Controlled Release Systems of Pluribioactive Antifungal Drugs

Abstract

Controlled release systems release at least one pluribioactive antifungal drug exhibiting at least one additional bioactivity from the group consisting of spermiostatic, antineoplastic, antibacterial, antirestenotic and antiviral activities. The drug release system is designed for use as a spermiostatic contraceptive, intravaginal ringed-mesh which may also exhibit antiviral activity, an in situ-forming implant for treating different forms of cancer and topical film for treating or preventing bacterial and fungal infections.

What is claimed is: 
     
         1 . A method for treating cancer comprising employing an antifungal drug selected from the group consisting of miconazole, ketoconazole, itraconazole, voriconazole, and amphotericin B, the antifungal drug exhibiting antineoplastic activity, wherein the antifungal drug is introduced into the body by means of a drug release system comprising an polymeric implant having the antifungal drug incorporated therein. 
     
     
         2 . A method for treating bacterial infections comprising employing an antifungal drug selected from the group consisting of miconazole, ketoconazole, itraconazole, voriconazole, and amphotericin B, the antifungal drug exhibiting antibacterial activity, wherein the antifungal drug is introduced into the body by means of a drug release system comprising an polymeric implant having the antifungal drug incorporated therein. 
     
     
         3 . A method for treating viral infections comprising employing an antifungal drug selected from the group consisting of miconazole, ketoconazole, itraconazole, voriconazole, and amphotericin B, the antifungal drug exhibiting antiviral activity, wherein the antifungal drug is introduced into the body by means of a drug release system comprising an polymeric implant having the antifungal drug incorporated therein. 
     
     
         4 . A method for preventing conception comprising employing an antifungal drug selected from the group consisting of miconazole, ketoconazole, itraconazole, voriconazole, and amphotericin B, the antifungal drug exhibiting spermiostatic activity, wherein the antifungal drug is introduced into the body by means of a drug release system comprising an polymeric implant having the antifungal drug incorporated therein. 
     
     
         5 . A method for preventing restenosis comprising employing an antifungal drug selected from the group consisting of miconazole, ketoconazole, itraconazole, voriconazole, and amphotericin B, the antifungal drug exhibiting antirestenosis activity, wherein the antifungal drug is introduced into the body by means of a drug release system comprising an polymeric implant having the antifungal drug incorporated therein.